BioNTech 22. Mai 2026 ASCO26: After ivonescimab stumble, rivals unveil their own bispecific data - FirstWord Pharma
Merck & Co. 22. Mai 2026 ASCO26: Merck & Co., Moderna detail melanoma survival findings for cancer vaccine - FirstWord Pharma
eLife 22. Mai 2026 In situ mutational screening and CRISPR interference define <i>apterous</i> cis-regulatory inputs during compartment boundary formation
eLife 22. Mai 2026 A quantitative pipeline for whole-mount deep imaging and analysis of multi-layered organoids across scales
eLife 22. Mai 2026 Developmental constraints mediate the reversal of temperature effects on the autumn phenology of European beech after the summer solstice
eLife 22. Mai 2026 Isolation of small extracellular vesicles from small volumes of blood plasma using size exclusion chromatography and density gradient ultracentrifugation
Merck & Co. 21. Mai 2026 ASCO26: Merck & Co.'s ADC combo bests Keytruda alone in NSCLC - FirstWord Pharma
FierceBiotech 21. Mai 2026 ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
Endpoints News 21. Mai 2026 #ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study
Endpoints News 21. Mai 2026 #ASCO26: Key head and neck cancer readouts from J&J, Corbus, Summit, Akero and Bicara
Endpoints News 21. Mai 2026 #ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBio
Merck & Co. 21. Mai 2026 ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer - Fierce Pharma